Nephrogenic Systemic Fibrosis News and Research

RSS

New high-performance, safe MRI contrast agent for 3D vascular mapping

Heart attack and stroke are the first and second leading causes of death in developed countries, respectively. As the disease often results in sudden death with few special prognostic symptoms, early diagnosis is very important.

10 Mar 2021

Novel MRI contrast agent shows strong potential as safer alternative to current products

Adding a contrast-enhancing agent to magnetic resonance imaging (MRI) significantly improves image quality and allows radiologists who interpret MRI scans to pick up subtle anatomic details and abnormalities that might otherwise be missed.

15 Dec 2020

MGH researchers develop potential alternative to gadolinium-based MRI contrast agents

A team of Massachusetts General Hospital researchers has developed a potential alternative to gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging.

15 Nov 2017

Researchers develop new iron oxide nanoparticles as contrast agent for MRI

A new, specially coated iron oxide nanoparticle developed by a team at MIT and elsewhere could provide an alternative to conventional gadolinium-based contrast agents used for magnetic resonance imaging procedures.

14 Feb 2017

Non-contrast MRA can be viable diagnostic alternative for patients with chronic kidney disease

Patients with diabetes or renal failure are at high risk for deadly and debilitating vascular diseases, however, the most common imaging tool to evaluate the blood vessels uses a contrast agent that can further damage the kidneys.

30 Sep 2016

Study evaluates long-term safety of infants after maternal MRI exposure

In an analysis that included more than 1.4 million births, exposure to magnetic resonance imaging (MRI) during the first trimester of pregnancy compared with nonexposure was not associated with increased risk of harm to the fetus or in early childhood, although gadolinium MRI at any time during pregnancy was associated with an increased risk of a broad set of rheumatological, inflammatory, or skin conditions and, possibly, for stillbirth or neonatal death, according to a study appearing in the September 6 issue of JAMA.

6 Sep 2016

Animal study highlights major safety concern regarding use of MRI contrast agents in patients

New results in animals highlight a major safety concern regarding a class of magnetic resonance imaging (MRI) contrast agents used in millions of patients each year, according to a paper published online by the journal Investigative Radiology.

26 Jun 2015

Study finds direct evidence of gadolinium deposition in neuronal tissues following contrast-enhanced MRI exams

Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were recently published online in the journal Radiology.

17 Mar 2015

Dotarem gets FDA approval for use in patients undergoing CNS MRI

The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging of the brain, spine and associated tissues of patients ages 2 years and older.

21 Mar 2013

Small numbers of ANA- and RP-negative patients with systemic sclerosis

There exists a very small subgroup of patients with systemic sclerosis who lack circulating antinuclear antibodies and who do not have Raynaud's phenomenon, research shows.

31 Dec 2012

Jefferson researchers to investigate mechanisms involved in nephrogenic systemic fibrosis

Researchers at the Jefferson Institute of Molecular Medicine were awarded almost $384,000 by the National Institutes of Health to investigate the mechanisms involved in the development of a serious and sometimes fatal disease, known as Nephrogenic Systemic Fibrosis, a rare skin disorder linked to Gadolinium-based contrast agents used in magnetic resonance (MRI and MRA) studies.

26 Oct 2012

Restrictive gadolinium-based contrast agent guidelines help prevent nephrogenic systemic fibrosis

A simple blood test may help prevent a serious complication associated with a contrast agent commonly used in MRI exams, according to a study published in the July issue of Radiology.

18 May 2011

Gadavist approved by FDA for use in central nervous system MRI scans

The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

16 Mar 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

Toshiba announces new Vantage Titan HSR 1.5T MR with high slew rate gradients

Certain MR exams such as advanced cardiac and neuro imaging require a system with enhanced gradients for better image quality and quicker exams. For these applications, Toshiba America Medical Systems, Inc. announces the new Vantage TitanTM HSR 1.5T MR with high slew rate gradients and new user interface, M-Power. Toshiba will showcase the new Vantage Titan HSR (pending 510k clearance) at this year's Radiological Society of North America (RSNA) annual meeting, held in Chicago, Nov. 28 - Dec. 3, 2010 (Booth #3435, South Hall).

2 Dec 2010

Toshiba announces multi-center trial to evaluate Time-SLIP Renal MR Angiography

Non-contrast MR angiography provides clear, high-quality images and can be used as an effective tool for diagnosing renal artery stenosis. To illustrate non-contrast MRA's ability as a diagnostic tool for renal artery stenosis, Toshiba has announced a multi-center trial to establish the clinical value of non-contrast Renal MRA using Time-SLIP.

29 Nov 2010

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, supports the U.S. Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF).

10 Sep 2010

GBCAs carry new warnings on their labels about risk of NSF: FDA

The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.